Could This New Weight-Loss Pill Disrupt the Entire Market? Here’s What You Should Know About Orforglipron

In a 52-week phase 3 study of 1,698 adults with type 2 diabetes, once-daily oral orforglipron beat oral semaglutide on blood sugar and weight loss.

Orforglipron reduced HbA1c and body weight more than the oral GLP-1 comparator.

The tradeoff was more nausea, vomiting, diarrhea, constipation, and treatment discontinuation.

If future studies confirm the results, an effective oral alternative to injectable GLP-1 drugs could expand access and simplify use.